Advertisement

Exploiting Nongenomic Estrogen Receptor-Mediated Signaling for the Development of Pathway-Selective Estrogen Receptor Ligands

  • C. Otto
  • S. Wessler
  • K.-H. Fritzemeier
Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/1)

Abstract

Different molecular mechanisms mediate the diverse biological effects of estrogens. The classical genomic mechanism is based on the function of the ER as a ligand-dependent transcription factor that binds to estrogen-response elements (EREs) in promoters of target genes to initiate gene expression. These direct genomic effects play a prominent role in the regulation of reproductive function. In contrast, nongenomic effects mediated by the classical ER have been demonstrated to activate PI3K, leading to the activation of endothelial NOS (eNOS) and hence vasorelaxation. Pathway-selective ER ligands might represent a novel option for hormone replacement therapy. Here we describe the identification and in vitro characterization of tool compounds that bind the ER reasonably well but exhibit low transcriptional activity on ERE-driven promoters. However, these compounds behave as potent stimulators of PI3K/Akt activation in vitro and lead to aortic vessel relaxation, a mechanism that is thought to be driven by nongenomic ER action. In a second set of experiments, we analyze how the in vitro pathway selectivity translates into the in vivo situation. We examine our tool compounds in comparison to estradiol and estren in the following paradigms: bone protection, uterine growth assays, and mammary gland assays.

Keywords

Estrogen Receptor Mammary Gland Aortic Ring Genomic Effect Swiss Webster Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varicchio L, Barone MV, Auricchio F (2001) PI3-kinase in concert with Src promotes the S-phase entry of estradiol-stimulated MCF-7 cells. EMBO J 20:6050–6059PubMedCrossRefGoogle Scholar
  2. Garcia-Segura LM, Azcoitia I, Don Carlos LL (2001) Neuroprotection by estradiol. Prog Neurobiol 63:29–60PubMedCrossRefGoogle Scholar
  3. Hart LL, Davie RR (2002) The estrogen receptor: more than the average transcription factor. Biochem Cell Biol 80:335–341PubMedCrossRefGoogle Scholar
  4. Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH (2004) Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 18:1599–1609PubMedCrossRefGoogle Scholar
  5. Islander U, Hasseus B, Erlandsson MC, Jochems C, Skrtic SM, Lindberg M, Gustafsson JA, Ohlsson C, Carlsten H (2005) Estren promotes androgen phenotypes in primary lymphoid organs and submandibular glands. BMC Immunol 6:16PubMedCrossRefGoogle Scholar
  6. Jakacka M, Ito M, Martinson F, Ishikawa T, Lee EJ, Jameson JL (2002) An estrogen receptor (ER)α deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signalling in vivo. Mol Endocrinol 16:2188–2201PubMedCrossRefGoogle Scholar
  7. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC (2001) Nongenotropic, sex-nonspecific signalling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730PubMedGoogle Scholar
  8. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert E, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal of bone loss in mice by nongenotropic signalling of sex steroids. Science 298:843–846PubMedCrossRefGoogle Scholar
  9. Krishan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU (2005) The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol 67:744–748CrossRefGoogle Scholar
  10. Liu Y, Teng CT (1992) Estrogen response module of the mouse lactoferrin gene contains overlapping chicken ovalbumin upstream promoter transcription factor and estrogen receptor-binding elements. Mol Endocrinol 6:355–364PubMedCrossRefGoogle Scholar
  11. Medina RA, Aranda E, Verdugo C, Kato S, Owen GI (2003) The action of ovarian hormones in cardiovascular disease. Biol Res 36:325–341PubMedCrossRefGoogle Scholar
  12. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406–5417PubMedCrossRefGoogle Scholar
  13. Norman AW, Litwack G (1987) Estrogens and progestins. In: Litwack G (ed) Hormones. Academic Press, London, pp 550–560Google Scholar
  14. Salom JB, Burguete MC, Perez-Asensio FJ, Centeno JM, Torregrosa G, Alborch E (2002) Acute relaxant effects of 17-β-estradiol through non-genomic mechanisms in rabbit carotid artery. Steroids 67:339–346PubMedCrossRefGoogle Scholar
  15. Simoncini T, Fornari L, Mannella P, Varone G, Caruso A, Liao JK, Genazzani AR (2002) Novel non-transcriptional mechanisms for estrogen receptor signalling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidyl 3-OH kinase. Steroids 67:935–939PubMedCrossRefGoogle Scholar
  16. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR (2004) Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69:537–542PubMedCrossRefGoogle Scholar
  17. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8(1):21–30PubMedCrossRefGoogle Scholar
  18. Wessler S, Otto C, Wilck N, Stangl V, Fritzemeier KH (2006) Identification of estrogen receptor ligands leading to activation of non-genomic signalling pathways while exhibiting only weak transcriptional activity. J Steroid Biochem Mol Biol 98:25–35PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.TRG Gynecology and AndrologyBayer Schering Pharma AGBerlinGermany
  2. 2.Paul Ehrlich InstitutLangenGermany

Personalised recommendations